T 1032

Drug Profile

T 1032

Latest Information Update: 17 Feb 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tanabe Seiyaku
  • Class Heart failure therapies
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cardiovascular disorders; Erectile dysfunction; Heart failure; Pulmonary arterial hypertension

Most Recent Events

  • 16 Feb 2006 Discontinued - Preclinical for Cardiovascular disorders in Japan (unspecified route)
  • 16 Feb 2006 Discontinued - Preclinical for Erectile dysfunction in Japan (unspecified route)
  • 16 Feb 2006 Discontinued - Preclinical for Heart failure in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top